Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended

Sumitomo Pharma President Hiroshi Nomura Despite an anticipated sales drop resulting from the end of its tie-up on Trulicity (dulaglutide), Sumitomo Pharma intends to maintain its field force in Japan as the company sees it an “asset” to attract future...read more